Ascendia

  MARKET NEWS

Lubrizol Launches Carbopol Polymers for Nutraceuticals With New EU Food-Grade Approval
Quotient Sciences Announces Major Investment in Sterile Fill/Finish Capacity in Response to Increasing Industry Demand
Flashpoint Therapeutics Announces $10M Seed Financing to Pioneer Nanotechnology-Enabled Medicines
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Pfizer & BioNTech Announce Positive Topline Data for mRNA-Based Combination Vaccine Program Against Influenza & COVID-19
Orchard Therapeutics Announces Additional Positive Data from Proof-of-Concept Study of OTL-203 in MPS-IH

  FEATURED EDITORIAL

  COMPANY PROFILE

Enteris BioPharma Inc., a wholly owned subsidiary of SWK Holdings Corp. (Nasdaq: SWKH), is a fully integrated development and manufacturing organization offering innovative oral drug delivery solutions. Since its founding in 2013, Enteris has adapted its oral drug delivery technology to advance multiple internal and client programs into the clinic. More recently, Enteris has completed a renovation of its 32,000-sq-ft GMP facility, including HPAPI containment and handling, in Boonton, NJ, enabling long-term partnerships for challenging solid oral drug product development from preclinical through commercial cGMP manufacturing. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Roquette Completes Acquisition of Qualicaps & Reinforces Global Position in the Pharmaceutical Industry

Roquette Completes Acquisition of Qualicaps & Reinforces Global Position in the Pharmaceutical Industry

This strategic investment creates a stronger leader, with an expanded global footprint, as well as an enriched offering of oral dosage solutions…..

Next-Generation Pharma Glass: SCHOTT AG Launches FIOLAX Pro Glass Tubing

Next-Generation Pharma Glass: SCHOTT AG Launches FIOLAX Pro Glass Tubing

With its borosilicate glass being the gold standard for storing life-saving medications for more than a century, the company is now taking the next steps by introducing improved glass tubing to the global pharma market…..

Elligo & Avallano Launching Patient-First, AI-Powered Clinical Trials Ecosystem

Elligo & Avallano Launching Patient-First, AI-Powered Clinical Trials Ecosystem

Elligo Health Research recently announced a partnership with Avallano to launch myTrialsConnect, a scalable research community powered by artificial intelligence (AI), that was built to serve….

ABVC BioPharma Entered a Term Sheet to License Global Rights of CNS Drugs With the Indications of MDD & ADHD to AiBtl BioPharma at 7-Million Valuation

ABVC BioPharma Entered a Term Sheet to License Global Rights of CNS Drugs With the Indications of MDD & ADHD to AiBtl BioPharma at $667-Million Valuation

ABVC BioPharma, Inc. recently announced it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with AiBtl BioPharma (AiBtl) for the company’s CNS drugs with the indications of….

  WHITEPAPERS & WEBINARS

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….

  WHITEPAPERS & WEBINARS

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.

Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared

…

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

By: Dr. Bahar Yeniad and Dr. Pieter van Delft

Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …

WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy

WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy

Direct compression is often used for tablet manufacturing because it is the shortest, most effective, and least complex method. The physical properties of active pharmaceutical ingredients (APIs) can, however, create a challenge for flowability and compressibility, and, as a result, …

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations. It shows the over-additive effect of using two excipients together and addresses how excipients’ viscosity-reducing ability depends on pH. The results show the effect of protein viscosity on …

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 8 – Drug Delivery
November 15 – Parenteral Contract Manufacturing